Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer

Jabbarzadeh Kaboli, Parham; Chen, Hsiao-Fan; Babaeizad, Ali; Roustai Geraylow, Kiarash; Yamaguchi, Hirohito; Hung, Mien-Chie

doi:10.1016/j.canlet.2024.216780

Cited by 9 publications

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Insights into medicinal attributes of imidazo[1,2‐a]pyridine derivatives as anticancer agents

Kumar,

Sharma,

Behl

et al. 2024

Archiv der Pharmazie

View full text Add to dashboard Cite

Cancer ranks among the most life‐threatening diseases worldwide and is continuously affecting all age groups. Consequently, many research studies are being carried out to develop new cancer treatments, but many of them experience resistance and cause severe toxicity to the patients. Therefore, there is a continuous need to design novel anticancer agents that are target‐based, have a higher potency, and have minimal toxicity. The imidazo[1,2‐a]pyridine (IP) pharmacophore has been found to be a prominent moiety in the field of medicinal chemistry due to its vast biological properties. Also, it holds immense potential for combating cancer with minimal side effects, depending on the substitution patterns of the core structure. IPs exhibit significant capability in regulating various cellular pathways, offering possibilities for targeted anticancer effects. The present review summarizes the anticancer profile of numerous IP derivatives synthesized and developed by various researchers from 2016 till now, as inhibitors of phosphoinositide‐3‐kinase/mammalian target of rapamycin (PI3K/mTOR), protein kinase B/mammalian target of rapamycin (Akt/mTOR), aldehyde dehydrogenase (ALDH), and tubulin polymerization. This review provides a comprehensive analysis of the anticancer activity afforded by the discussed IP compounds, emphasizing the structure–activity‐relationships (SARs). The aim is also to underscore the potential therapeutic future of the IP moiety as a potent partial structure for upcoming cancer drug development and to aid researchers in the field of rational drug design.

show abstract